Oncology Commons^™

Chronic Ethanol Exposure Enhances The Aggressiveness Of Breast Cancer: The Role Of P38Γ, Mei Xu, Siying Wang, Zhenhua Ren, Jacqueline A. Frank, Xiuwei H. Yang, Zhuo Zhang, Zun-Ji Ke, Xianglin Shi, Jia Luo

Pharmacology and Nutritional Sciences Faculty Publications

Both epidemiological and experimental studies suggest that ethanol may enhance aggressiveness of breast cancer. We have previously demonstrated that short term exposure to ethanol (12–48 hours) increased migration/invasion in breast cancer cells overexpressing ErbB2, but not in breast cancer cells with low expression of ErbB2, such as MCF7, BT20 and T47D breast cancer cells. In this study, we showed that chronic ethanol exposure transformed breast cancer cells that were not responsive to short term ethanol treatment to a more aggressive phenotype. Chronic ethanol exposure (10 days - 2 months) at 100 (22 mM) or 200 mg/dl (44 mM) caused the …

Beyond The One-Locus-One-Mirna Paradigm: Microrna Isoforms Enable Deeper Insights Into Breast Cancer Heterogeneity., Aristeidis G Telonis, Phillipe Loher, Yi Jing, Eric R Londin, Isidore Rigoutsos

Computational Medicine Center Faculty Papers

Here we describe our study of miRNA isoforms (isomiRs) in breast cancer (BRCA) and normal breast data sets from the Cancer Genome Atlas (TCGA) repository. We report that the full isomiR profiles, from both known and novel human-specific miRNA loci, are particularly rich in information and can distinguish tumor from normal tissue much better than the archetype miRNAs. IsomiR expression is also dependent on the patient's race, exemplified by miR-183-5p, several isomiRs of which are upregulated in triple negative BRCA in white but not black women. Additionally, we find that an isomiR's 5' endpoint and length, but not the genomic …

Oncolog, Volume 60, Number 06, June 2015, Bryan Tutt, Joe Munch, U. Arizor

OncoLog MD Anderson's Report to Physicians (All issues)

• New Breast Imaging Modalities Show promise for Cancer Screening and Staging: New technology to supplement digital mammography may improve breast cancer screening and diagnosis. Although some of these new imaging modalities are still under development, others are already in clinical use as adjuncts to mammography for breast cancer screening and staging.
• Addressing Sexual Dysfunction in Cancer Survivors: Cancer treatments carry a host of side effects that can affect patients' ability to have and enjoy sex. The sexual dysfunction arising from these side effects, which include functional changes, can often be addressed, but uncovering sexual dysfunction can prove challenging.
• HOUSE CALL: …

Oncolog, Volume 60, Number 05, May 2015, Sarah Bronson, Bryan Tutt, U. Arizor

OncoLog MD Anderson's Report to Physicians (All issues)

• Algorithm for Treating Advanced Ovarian Cancer Increases Complete Resection Rate: Most ovarian cancers have spread beyond the ovary by the time they are diagnosed, and they often recur even after responding to primary treatment. Researchers at The University of Texas MD Anderson Cancer Center aim to improve patient outcomes by changing the standard approach to newly diagnosed advanced ovarian cancer.
• Clinical Trials Explore Systemic Treatments for Brain Metastases from Breast Cancer: Brain metastases from breast cancer are difficult to treat because many of the systemic drugs that are effective against breast cancer cannot cross the blood-brain barrier. But researchers at …

Plasma Tnf-Α And Soluble Tnf Receptor Levels After Doxorubicin With Or Without Co-Administration Of Mesna-A Randomized, Cross-Over Clinical Study, John Hayslip, Emily Van Meter Dressler, Heidi L. Weiss, Tammy J. Taylor, Mara D. Chambers, Teresa Noel, Sumitra Miriyala, Jeriel T. R. Keeney, Xiaojia Ren, Rukhsana Sultana, Mary Vore, D. Allan Butterfield, Daret St. Clair, Jeffrey A. Moscow

Markey Cancer Center Faculty Publications

PURPOSE: Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer therapy. Recent preclinical observations have suggested that CICI can be mediated by chemotherapy-induced plasma protein oxidation, which triggers TNF-α mediated CNS damage. This study evaluated sodium-2-mercaptoethane sulfonate (Mesna) co-administration with doxorubicin to reduce doxorubicin-induced plasma protein oxidation and resultant cascade of TNF-α, soluble TNF receptor levels and related cytokines.

METHODS: Thirty-two evaluable patients were randomized using a crossover design to receive mesna or saline in either the first or second cycle of doxorubicin in the context of a standard chemotherapy regimen for either non-Hodgkin lymphoma or breast …

Oncolog, Volume 60, Number 04, April 2015, Jill Deisigne, Joe Munch, Bryan Tutt, Sarah Bronson

OncoLog MD Anderson's Report to Physicians (All issues)

• Multidisciplinary Globe-Sparing Treatment for Lacrimal Gland Carcinoma Preserves Vision and Minimizes Morbidity: Until recently, the treatment of lacrimal gland carcinoma almost always required removal of the eye. But for some patients with these tumors, globe-sparing surgery followed by radiation therapy can preserve vision and decrease ocular morbidity and facial disfigurement.
• Novel Trial Design Streamlines Development of Breast Cancer Therapies: Developing a cancer-fighting drug can take around a billion dollars and a dozen or more years. Even then, fail in clinical trials. To identify effective cancer therapies more quickly and efficiently, researchers have tuned to an innovative clinical model in which …

Cytometric Characterization Of Circulating Tumor Cells Captured By Microfiltration And Their Correlation To The Cellsearch(®) Ctc Test., Daniel L Adams, Steingrimur Stefansson, Christian Haudenschild, Stuart S Martin, Monica Charpentier, Saranya Chumsri, Massimo Cristofanilli, Cha-Mei Tang, R Katherine Alpaugh

Pathology Faculty Publications

Recent studies reporting hundreds, to thousands, of circulating tumor cells (CTCs) in the blood of cancer patients have raised questions regarding the prevalence of CTCs, as enumerated by the CellSearch(®) CTC Test. Although CellSearch has been shown to consistently detect clinically relevant CTCs; the ability to only capture EpCAM positive cells has led to speculation that it captures limited subsets of CTCs. In contrast, alternative approaches to CTC isolation are often cited as capturing large numbers of CTCs from patient blood. Not surprisingly the number of cells isolated by alternative approaches show poor correlations when compared to CellSearch, even when …